Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

Study Questions:

What is the efficacy of macitentan, a new dual endothelin-receptor antagonist (ETa), in patients with pulmonary arterial hypertension (PAH) using endpoints of morbidity and mortality in a long-term trial?